Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer.
Where this comes from
- Record sourced from PubMed, PMID 39428325.
- Also identified by DOI 10.1016/j.eururo.2024.10.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Next-generation prostate-specific membrane antigen (PSMA) positron emission tomography imaging provides unprecedented accuracy for prostate cancer (PC) detection and can provide detailed disease metrics, which we summarize as a PSMA spatial biomarker (PSMA-SB). Overall survival data confirm that PSMA-SB can differentiate aggressive PC from indolent PC. PSMA-SB maps could be integrated with multiomics data to improve understanding of total-body cancer heterogeneity and phenotype.
Medical subject headings
- Prostatic Neoplasms
- Glutamate Carboxypeptidase II
- Antigens, Surface
- Positron-Emission Tomography
- Biomarkers, Tumor